A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

This study has suspended participant recruitment.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002362
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: March 2000

November 2, 1999
June 23, 2005
August 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002362 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients

This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.

Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.

Interventional
Phase 3
Endpoint Classification: Safety Study
Primary Purpose: Treatment
HIV Infections
  • Drug: Abacavir sulfate
  • Drug: Efavirenz
  • Drug: Emtricitabine
  • Drug: Stavudine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
Not Provided
Not Provided
Not Provided

Inclusion Criteria

You may be eligible if you:

  • Are HIV-positive and generally healthy.
  • Have a viral load of 5,000 copies/ml or more.
  • Have CD4 cell counts of 200 cells/mm3 or more.
  • Are age 18 or older.
  • Agree to practice sexual abstinence or use effective barrier methods of birth control (such as condoms).

Exclusion Criteria

You will not be eligible if you:

  • Have ever taken anti-HIV drugs for 3 days or more.
  • Have had certain AIDS-related infections.
  • Have had severe diarrhea within the past 30 days.
  • Are unable to eat at least 1 meal a day due to nausea, vomiting, or stomach pain.
  • Are being treated for active tuberculosis (TB).
  • Are pregnant or breast-feeding.
  • Use illegal drugs or alcohol that make it difficult for you to take study drugs or keep clinic appointments.
  • Are taking certain medications, or have certain other conditions or diseases (see the technical summary for more detail).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002362
298B, FTC-301
Not Provided
Not Provided
Triangle Pharmaceuticals
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
March 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP